Hjem › KOLS › New York › Queens
Kliniske studier for KOLS i Queens, NY
4 studier for KOLS søker deltakere på steder i og rundt Queens (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RekruttererFase 3
- Research Site, Massapequa · 19 mi unna
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RekruttererFase 3
- New York Hospital Queens- Site Number : 8400058, Flushing · 6 mi unna
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RekruttererFase 3
- Research Site, Massapequa · 19 mi unna
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
RekruttererFase 2/3
- New York Presbyterian Queens, Flushing · 6 mi unna
KOLS-studier i andre byer
- Philadelphia, PA23 studier
- Miami, FL18 studier
- Birmingham, AL17 studier
- Boston, MA17 studier
- Houston, TX15 studier
- Orlando, FL15 studier
- Baltimore, MD14 studier
- Chicago, IL14 studier
- Dallas, TX12 studier
- Pittsburgh, PA12 studier
- New York City, NY11 studier
- Ann Arbor, MI10 studier
Andre studier i Queens
- Brystkreft63 studier
- Ikke-småcellet lungekreft49 studier
- Kolorektal kreft31 studier
- Metastatisk kreft28 studier
- Eggstokkreft28 studier
- Prostatakreft27 studier
- Kreft (alle typer)26 studier
- Endometriekreft25 studier
- Lungekreft22 studier
- Akut myelogen leukemi21 studier
- Plateepitelcancer i hode og hals20 studier
- Multipelt myelom20 studier
Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.